James N Palmer, Nithin D Adappa, Rakesh K Chandra, Greg E Davis, Mahboobeh Mahdavinia, John Messina, Randall A Ow, Zara M Patel, Anju T Peters, Harry Sacks, Rodney J Schlosser, Raj Sindwani, Zachary M Soler, Andrew A White, Sarah K Wise, Ramy A Mahmoud
BACKGROUND: Chronic rhinosinusitis (CRS) is a prevalent inflammatory disease. No medications are Food and Drug Administration-approved for the most common form, CRS without nasal polyps (also called "chronic sinusitis"). Novel biomechanics of the exhalation delivery system deliver fluticasone (EDS-FLU; XHANCE) to sinonasal areas above the inferior turbinate, especially sinus drainage pathways not reached by standard-delivery nasal sprays. OBJECTIVE: Assess EDS-FLU efficacy for CRS (irrespective of nasal polyps)...
January 5, 2024: Journal of Allergy and Clinical Immunology in Practice